 |
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
Metsera announced on Nov. 4 that it received a revised $86.20 bid from Novo that is worth about $10B.
That tops the $70 per-share bid ($8.1B) that is already accepted from Pfizer. Metsera informed Pfizer it considers Novo's offer a “superior company proposal,” which gives Pfizer two days to up the ante.
Pfizer CEO Albert Bourla said in a conference call that Nova's bid is “illusory” because it violates antitrust law and there is a high risk it will never be consummated.
Novo (maker of Ozempic & Wegovy) ranks behind Eli Lilly (Mounjaro & Zepbound) in the weight-loss drug derby. Pfizer is eager to break into the field via the takeover of Metsera.
Teneo’s TJ White (a veteran of Sloane & Co and Sard Verbinnen) handles the Metsera business in his post as senior managing director in the transactions & strategic situations practice.
Prosek Partners handles New York’s Tilray Brands, craft beer & cannabis operation, as it acquires BrewDog, a leading British independent beer producer in the UK, for $45M.
Brunswick Group handles Zurich Insurance as it agrees to buy UK-based Beazley specialty insurer in a deal valued at $11B.
FGS Global represents Brink’s as it agrees to acquire NCR Atleos, which relies on Collected Strategies, in a $6.6B cash & stock deal to create a leading fintech infrastructure company. (Updated)
A January article in O’Dwyer’s proposes that in 2026, the strongest financial brands will not simply tell compelling stories—they will “signal readiness.”
C Street Advisory Group is working the Chapter 11 filing of Axip Energy Services as it unloads its nearly all of its assets to deal with a heavy debt load.
